Methods
cough, respiratory illness, ARI
INFLUENZA, VIRUS INFECTION, INFLUENZA
We conducted a cluster‐randomized stepped‐wedge trial of point‐of‐care molecular influenza testing coupled with antiviral treatment with baloxavir or oseltamivir in residents of 14 homeless shelters in Seattle, WA, USA. Residents ≥3 months with cough or ≥2 acute respiratory illness (ARI) symptoms and onset <7 days were eligible. In control periods, mid‐nasal swabs were tested for influenza by reverse transcription polymerase chain reaction (RT‐PCR). The intervention period included on‐site rapid molecular influenza testing and antiviral treatment for influenza‐positives if symptom onset was <48 h. The primary endpoint was monthly influenza virus infections in the control versus intervention periods. Influenza whole genome sequencing was performed to assess transmission and antiviral resistance.